🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚨 New paper in npj Journals Precision Oncology! We show that radiomics + pathomics improves prediction of recurrence in early NSCLC, ICI response in advanced NSCLC, & chemo response in SCLC. 📌 A step forward in #AI precision oncology for lung cancer. 🔗 rdcu.be/eppuU

The new tumour board? ⁦Nature Cancer⁩ - multimodel AI agent integrates patient data using GPT-4, MSI/KRAS/BRAF slides, radiologic images, OncoKB/PubMed/Google - AI agent makes correct clinical decision in 91% cases ⁦Jakob Nikolas Kather⁩ ⁦OncoAlert⁩ nature.com/articles/s4301…

【The current and emerging immunotherapy paradigm in SCLC】 📖Review ES-SCLCの初回治療、LS-SCLCの地固め療法、そして再発後の治療まで最新のエビデンスを網羅したレビュー📝  📚Nature Cancer 2025 nature.com/articles/s4301…

Very happy to see the first review of the IASLC Basic and Translational Science Committee, just out in JTO & JTO CRR. 📑Here, we discuss the recent advances in basic and translational research regarding non-small cell lung cancer. #LCSM #NSCLC CRCL sciencedirect.com/science/articl…

Découverte de l'#ASCO25 par le groupe IFCT constitué des représentants des 10 centres les plus actifs dans les recrutements des études cliniques en 2024 : la convivialité était au rendez-vous, pour partager toutes les actualités en oncologie pulmonaire !

🤖 How Robot-Assisted Lung Cancer Surgery is Changing the Game. Dr. Jeff Yang MD FACS of Mass General Surgery & Harvard Medical School explains how robotic surgery—with smaller incisions and faster recovery—is transforming lung cancer care. 🔬

A pooled analysis of datopotamab deruxtecan in patients with EGFR–mutated NSCLC - Journal of Thoracic Oncology jto.org/article/S1556-… JTO & JTO CRR LungCancerRx 🫁💊 Interesting analysis ahead of U.S. FDA PDUFA date: July 12, 2025 Will we see another option in EGFRm NSCLC? OncoAlert

Advances in Molecular Pathology & Therapy of NSCLC 🌟Precision oncology is no longer optional. This review maps the molecular landscape of NSCLC (EGFR, ALK, KRAS, etc.), resistance, spatial omics & AI, and shows how biology is reshaping lung cancer treatment. 1/2 OncoAlert

Can we spare adj chemo in resected EGFR NSCLC? Probably no. Our Cochrane metanalysis shows no OS difference with 1st/2nd gen EGFR TKI vs adj chemo. Relapses during the EGFR TKIs drug off time were higher compared to adj chemo (45% vs 30%). Cochrane cochranelibrary.com/cdsr/doi/10.10…

A comprehensive review on molecular basics along with current and emerging therapeutic options in small cell lung cancer! OncoAlert #Cancer #Oncology #lungcancer #MedTwitter #MedX doi.org/10.1038/s43018…

🚀 New breakthrough in immunotherapy prediction! Only ~30% of solid tumor patients benefit from ICIs—so researchers developed HAPIR, a Hallmark gene set-based model trained on transcriptomic data 🧬 ✅ Validated across 6 TIGER cohorts & TCGA-SKCM ✅ AUROC 0.778 (vs PD-1: 0.678,

🆕article in press: DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small cell lung cancer annalsofoncology.org/article/S0923-… Mark Awad Biagio Ricciuti, MD, PhD

Recent Advance of KRAS-G12C Inhibitors for Cancer Therapy - ScienceDirect sciencedirect.com/science/articl…

🧵Institut national du cancer se félicite de l’adoption par l’Assemblée nationale de la proposition de loi portant création du registre national des cancers. Il en assurera le pilotage et la mise en œuvre. Cela représente un bond dans la surveillance épidémiologique des cancers sur le territoire.

Outcomes of Solid Organ Transplant Recipients With Advanced Cancers Receiving Immune Checkpoint Inhibitors JAMA Oncology doi.org/10.1001/jamaon… 🔎128 studies, 343 SOTRs 👉Acute rejection: 36.2%; graft loss: 18%, lower risk w/ steroids & mTOR 👉ORR: 31% 🧐ICI my be considered in

🔗 COALA project website is now live! 👉 coala-lung.org A national multidisciplinary consortium supported by the Institut national du cancer bringing together experts in lung cancer research to improve outcome of lung cancer patients with oncogenic addiction.

🚨 #Lungcancer survival has more than doubled. New real-world data from France shows 3-year survival for lung adenocarcinoma rose from 16.3% (2000) to 38.6% (2020) driven by earlier diagnosis & targeted treatment. This is what progress looks like. But it must reach everyone who

🔬Pour une recherche sur échantillons biologiques humains française libérée des freins administratifs inutiles ➡️Un enjeu crucial pour l’innovation médicale en France 👉Déjà plus de 490 signataires : app.evalandgo.com/f/285125/4q5DU… #innovation #santé #CODECOH #RechercheClinique

🆕 Nature study on #lungcancer in never-smokers challenges long-held assumptions. ✅ Air pollution linked to key mutations ✅ EGFR most common in East Asia ❌ Secondhand smoke not a major factor - minimal genomic impact 68% of our EGFR+ UK members (2024 data) are never-smokers

Single-Agent Divarasib in Patients With KRAS G12C–Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study |Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…